RADNOR, Pa., June 1, 2021 /PRNewswire/ — The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors that a securities fraud class action lawsuit has been filed against FibroGen, Inc. (NASDAQ: FGEN) (“FibroGen”) on behalf of those who purchased or acquired FibroGen securities and/or sold put options from October 18, 2017 through April 6, 2021, inclusive (the “Class Period”).
KTMC Logo (PRNewsfoto/Kessler Topaz Meltzer & Check, LLP)
Investor Deadline Reminder: Investors who purchased or…

Click here to view the original article.